Notable 52-Week Highs and Lows 10/10: (TSRO) (DE) (FANG) High; (MYGN) (NTLA) Low

October 10, 2016 2:52 PM EDT

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

52-Week High:
  • TESARO, Inc. (Nasdaq: TSRO) $122.89. Tesaro and ENGOT, the European Network for Gynaecological Oncological Trial groups, announced the presentation of the niraparib Phase 3 ENGOT-OV16/NOVA clinical trial results at the ESMO 2016 Congress, the congress of the European Society for Medical Oncology (ESMO), by Dr. Mansoor Raza Mirza, M.D., Medical Director of the Nordic Society of Gynecologic Oncology (NSGO) and principal investigator on the ENGOT-OV16/NOVA trial.

  • Deere & Co. (NYSE: DE) $89.34. Wells Fargo upgraded Deere from Market Perform to Outperform today.

  • Diamondback Energy, Inc. (Nasdaq: FANG) $105.46. Diamondback Energy provided an operational update for the quarter ended September 30, 2016, increased 2016 production outlook and introduced preliminary guidance for the full year of 2017. For more color, click here.

  • STMicroelectronics (NYSE: STM) $8.41. Baird upgraded STMicroelectronics from Neutral to Outperform and moved its price target from $7 to $11.
52-Week Low:
  • Myriad Genetics, Inc. (Nasdaq: MYGN) $18.58. Myriad Genetics announced that its myChoice HRD test identified more than double the number of patients who may benefit from treatment with niraparib than were identified by germline BRCA testing alone. The myChoice HRD test was evaluated in the NOVA study (NCT01847274) of nirarapib, an investigational oral PARP inhibitor being developed by TESARO.

  • Intellia Therapeutics Inc. (Nasdaq: NTLA) $14.29. Intellia Therapeutics shares continuing lower following a sharp drop last Thursday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Special Reports

Related Entities

Robert W Baird, Wells Fargo

Add Your Comment